Erin M. Bange

918 total citations
21 papers, 198 citations indexed

About

Erin M. Bange is a scholar working on Oncology, Public Health, Environmental and Occupational Health and Economics and Econometrics. According to data from OpenAlex, Erin M. Bange has authored 21 papers receiving a total of 198 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 9 papers in Public Health, Environmental and Occupational Health and 9 papers in Economics and Econometrics. Recurrent topics in Erin M. Bange's work include Economic and Financial Impacts of Cancer (8 papers), Telemedicine and Telehealth Implementation (6 papers) and Cancer survivorship and care (5 papers). Erin M. Bange is often cited by papers focused on Economic and Financial Impacts of Cancer (8 papers), Telemedicine and Telehealth Implementation (6 papers) and Cancer survivorship and care (5 papers). Erin M. Bange collaborates with scholars based in United States, United Kingdom and Finland. Erin M. Bange's co-authors include Ronac Mamtani, Timothy J. Brown, Wei‐Ting Hwang, Evan Alley, Melina E. Marmarelis, Corey J. Langer, Abigail Doucette, Christine Ciunci, Roger B. Cohen and Jeffrey C. Thompson and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Nature Reviews Clinical Oncology.

In The Last Decade

Erin M. Bange

19 papers receiving 196 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Erin M. Bange United States 7 115 51 41 29 25 21 198
Anna Rachelle Mislang Australia 11 130 1.1× 62 1.2× 18 0.4× 31 1.1× 43 1.7× 26 298
Lydia Cairncross South Africa 7 182 1.6× 27 0.5× 18 0.4× 22 0.8× 27 1.1× 26 264
Madison Grogan United States 10 190 1.7× 65 1.3× 31 0.8× 19 0.7× 20 0.8× 30 268
Gabriela Sousa Portugal 8 71 0.6× 36 0.7× 19 0.5× 32 1.1× 16 0.6× 35 163
Leigh Boehmer United States 9 96 0.8× 64 1.3× 53 1.3× 24 0.8× 10 0.4× 42 253
Jared D. Acoba United States 12 171 1.5× 50 1.0× 45 1.1× 26 0.9× 50 2.0× 39 345
Anna Demetriou Cyprus 8 161 1.4× 18 0.4× 31 0.8× 32 1.1× 12 0.5× 17 253
Victoria Kaestner United States 6 156 1.4× 58 1.1× 26 0.6× 46 1.6× 59 2.4× 7 308
Hans‐Peter Goertz United States 9 83 0.7× 41 0.8× 24 0.6× 35 1.2× 47 1.9× 17 324
Deirdre Fitzpatrick United Kingdom 8 88 0.8× 21 0.4× 51 1.2× 23 0.8× 19 0.8× 21 220

Countries citing papers authored by Erin M. Bange

Since Specialization
Citations

This map shows the geographic impact of Erin M. Bange's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erin M. Bange with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erin M. Bange more than expected).

Fields of papers citing papers by Erin M. Bange

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erin M. Bange. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erin M. Bange. The network helps show where Erin M. Bange may publish in the future.

Co-authorship network of co-authors of Erin M. Bange

This figure shows the co-authorship network connecting the top 25 collaborators of Erin M. Bange. A scholar is included among the top collaborators of Erin M. Bange based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erin M. Bange. Erin M. Bange is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Seier, Kenneth, Erin M. Bange, Allison Lipitz‐Snyderman, et al.. (2025). Cancer Patient Perspectives on Clinical Trial Discussion and Informed Consent Through Telemedicine. JCO Oncology Practice. 21(10). 1439–1446. 1 indexed citations
2.
Bange, Erin M. & John K. Lin. (2025). Time Toxicity of Clinical Trials—Better Than Feared. JAMA Network Open. 8(4). e255044–e255044. 1 indexed citations
3.
Bange, Erin M., Anne S. Reiner, Susan Chimonas, et al.. (2025). Pilot study of an enhanced telehealth program for patients with prostate cancer.. Journal of Clinical Oncology. 43(16_suppl). 1647–1647.
4.
Bange, Erin M., et al.. (2024). Telemedicine and Cancer Care. The Cancer Journal. 30(1). 8–15. 7 indexed citations
5.
Rendle, Katharine A., Andy S.L. Tan, Bonnie Spring, et al.. (2024). A Framework for Integrating Telehealth Equitably across the cancer care continuum. JNCI Monographs. 2024(64). 92–99. 6 indexed citations
6.
Bange, Erin M., et al.. (2024). The feasibility and acceptability of home phlebotomy for patients with cancer. JNCI Cancer Spectrum. 8(6). 1 indexed citations
7.
Bange, Erin M., Allison Lipitz‐Snyderman, Gilad J. Kuperman, et al.. (2024). Transforming patient-centered cancer care using telehealth: the MATCHES Center. JNCI Monographs. 2024(64). 76–82. 2 indexed citations
8.
Seier, Kenneth, Erin M. Bange, Bobby Daly, et al.. (2024). Perspectives on Telemedicine Visits Reported by Patients With Cancer. JAMA Network Open. 7(11). e2445363–e2445363. 2 indexed citations
9.
Bange, Erin M., Timothy J. Brown, Andrea Bilger, et al.. (2023). Are we ready to mitigate time toxicity of cancer care? Oncologists’ perceptions on digital interventions to fast-track cancer care.. Journal of Clinical Oncology. 41(16_suppl). 1537–1537. 1 indexed citations
10.
Bange, Erin M., Yimei Li, Pallavi Kumar, et al.. (2023). The association between telemedicine, advance care planning, and unplanned hospitalizations among high‐risk patients with cancer. Cancer. 130(4). 636–644. 5 indexed citations
11.
West, Howard, Erin M. Bange, & Fumiko Chino. (2023). Telemedicine as patient-centred oncology care: will we embrace or resist disruption?. Nature Reviews Clinical Oncology. 20(10). 659–660. 4 indexed citations
12.
Szperka, Christina L., Svetlana Ostapenko, John T. Farrar, et al.. (2023). Patient headache questionnaires can improve headache diagnosis and treatment in children. Headache The Journal of Head and Face Pain. 63(10). 1359–1371. 6 indexed citations
13.
Bange, Erin M., et al.. (2022). Accuracy of a Text Intervention to Minimize the Burden of Cancer Care Among Patients Treated With Immune Checkpoint Inhibitors. JAMA Network Open. 5(8). e2228452–e2228452. 5 indexed citations
14.
Bange, Erin M., Timothy J. Brown, Wenrui Li, et al.. (2022). Saving TIME: Accuracy of a text intervention to minimize the time burden of cancer care.. Journal of Clinical Oncology. 40(16_suppl). 6527–6527.
15.
Freyer, Craig W., Erin M. Bange, Sarah Skuli, et al.. (2021). Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome in a Patient With Heterozygous CFHR3/CFHR1 Deletion Treated With Eculizumab. Clinical Lymphoma Myeloma & Leukemia. 21(11). e845–e849. 9 indexed citations
16.
Brown, Timothy J., Ronac Mamtani, & Erin M. Bange. (2021). Immunotherapy Adverse Effects. JAMA Oncology. 7(12). 1908–1908. 16 indexed citations
17.
Sun, Lova, Anh N. Le, Abigail Doucette, et al.. (2020). Rates of COVID-19–Related Outcomes in Cancer Compared With Noncancer Patients. JNCI Cancer Spectrum. 5(1). 27 indexed citations
18.
Bange, Erin M., Melina E. Marmarelis, Wei‐Ting Hwang, et al.. (2019). Impact of KRAS and TP53 Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With STK11-Mutated Advanced Non–Small-Cell Lung Cancer. JCO Precision Oncology. 3(3). 1–11. 57 indexed citations
19.
Marmarelis, Melina E., Erin M. Bange, Stephen Bagley, et al.. (2018). P1.01-64 Impact of STK11 Co-Mutation on Outcomes Following Immunotherapy Among Patients with TP53 and KRAS Mutated Stage IV NSCLC. Journal of Thoracic Oncology. 13(10). S486–S486. 2 indexed citations
20.
Bange, Erin M., et al.. (2018). Evidence for and Against Green Tea and Turmeric in the Management of Chronic Lymphocytic Leukemia. Clinical Lymphoma Myeloma & Leukemia. 18(10). e421–e426. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anna Rachelle Mislang Breakdown of academic impact, for papers by Lydia Cairncross Breakdown of academic impact, for papers by Madison Grogan Breakdown of academic impact, for papers by Gabriela Sousa Breakdown of academic impact, for papers by Leigh Boehmer Breakdown of academic impact, for papers by Jared D. Acoba Breakdown of academic impact, for papers by Anna Demetriou Breakdown of academic impact, for papers by Victoria Kaestner Breakdown of academic impact, for papers by Hans‐Peter Goertz Breakdown of academic impact, for papers by Deirdre Fitzpatrick
Rankless by CCL
2026